HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clarins S&E

This article was originally published in The Rose Sheet

Executive Summary

Cosmetics division third quarter sales benefit from diversification of Clarins brand with Clarins Men skin care debut and U.S. launch of Hugo Boss Boss In Motion men's fragrance, Parisian firm reports in 1third quarter sales release Oct. 18. Consolidated sales for the quarter were up 3.4% to $204.7 mil. For the nine months, Clarins brand sales rose 1.4% to $388.6. (€1=$.97) at average exchange rates, and Thierry Mugler grew 7.1% to $115.7 mil. Azzaro sales increased 3.1% to $66.1mil., and Perfume Distribution sales were $63.4 mil., up 5.8%...

You may also be interested in...



US/India Operation Intercepts Unapproved Drugs, Drug/Device Products

Nearly 500 shipments of illegal and unapproved prescription drugs and combination medical devices were seized at US borders thanks to Operation Broadsword.

Two Companies, Two BARDA Contracts, Two Approaches To Coronavirus

Sanofi follows Janssen in teaming up with HHS' BARDA to develop a COVID-19 vaccine; using technology platform of its Flublok vaccine, Sanofi expects to enter clinical trials in 1 to 1 ½ years.

Tech Transfer Roundup: Be Cool Therapeutics Sees Potential In Mimicking Hibernation

Biotech licenses drug composition patents from University of Alaska Fairbanks for study in several disease states. Gilead seeks long-acting HIV therapy or prevention with broadly neutralizing antibodies discovered by Rockefeller U.

UsernamePublicRestriction

Register

RS010683

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel